GENEONE LIFE SCIENCE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,400 KRW | -1.44% |
|
+5.73% | -15.49% |
| Sales 2022 | 48.72B 35.52M | Sales 2023 | 40.2B 29.31M | Capitalization | 222B 162M |
|---|---|---|---|---|---|
| Net income 2022 | -38.15B -27.81M | Net income 2023 | -77.77B -56.69M | EV / Sales 2022 | 10.8 x |
| Net cash position 2022 | 25.94B 18.91M | Net Debt 2023 | 7.17B 5.23M | EV / Sales 2023 | 5.71 x |
| P/E ratio 2022 |
-14.5
x | P/E ratio 2023 |
-2.84
x | Employees | 75 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 91.05% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.44% | ||
| 1 week | +5.73% | ||
| Current month | -5.33% | ||
| 1 month | -10.61% | ||
| 3 months | -8.75% | ||
| 6 months | -18.64% | ||
| Current year | -15.49% |
1 week
2 240.00
2 655.00
1 month
2 225.002 950.00
Current year
2 225.003 265.00
1 year
2 225.006 420.00
3 years
2 225.0039 200.00
5 years
1 490.0039 200.00
10 years
1 490.0039 200.00
| Managers | Title | Age | Since |
|---|---|---|---|
Young-Geun Park
CEO | Chief Executive Officer | 60 | - |
Won-Il Kim
CTO | Chief Tech/Sci/R&D Officer | 52 | - |
Byung-Moon Cho
BRD | Director/Board Member | 64 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Byung-Moon Cho
BRD | Director/Board Member | 64 | - |
Young-Geun Park
CEO | Chief Executive Officer | 60 | - |
Sang-Don Kim
BRD | Director/Board Member | 58 | 20-03-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 2 M€ | -.--% | ||
| 0.00% | 7 M€ | +1.91% | - | |
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +0.83% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 2,400 | -1.44% | 240,033 |
| 24-04-22 | 2,435 | +2.74% | 551,305 |
| 24-04-19 | 2,370 | +3.72% | 2,049,884 |
| 24-04-18 | 2,285 | +1.33% | 135,199 |
| 24-04-17 | 2,255 | +0.22% | 163,343 |
End-of-day quote Korea S.E., April 22, 2024
More quotes
GeneOneLifeScience, formerly VGX International, Inc., is a Korea-based company engaged in textile and biopharmaceutical businesses. The Company is a biomedical contract manufacturing organization (CMO). Its textile business engages in the provision of wicks under the brand name of INTERON, which are used in dress shirts, suits and caps. Its biopharmaceutical business engages in the research, development and manufacture of biomedical, plasmid deoxyribonucleic acid (DNA) and DNA vaccines. It also engaged in the leasing of nonresidential buildings.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -15.49% | 141M | |
| +3.13% | 42.11B | |
| +48.83% | 40.08B | |
| +8.49% | 40B | |
| -10.82% | 26.87B | |
| +8.26% | 24.58B | |
| -23.69% | 18.44B | |
| +1.58% | 11.94B | |
| +32.83% | 11.66B | |
| +6.63% | 11.01B |
- Stock Market
- Equities
- A011000 Stock
